TrianglePembrolizumab (NCT05568550)
Pembrolizumab trial for Prostate Cancer (NCT05568550). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with high-risk or very-high-risk prostate cancer without distant metastases. Regional lymph nodes may be involved; prior hormone therapy is limited to ninety days.
The idea: pembrolizumab releases an immune brake; olaparib blocks PARP-mediated DNA repair. Both join radiation and hormone therapy. The open arm gives seventeen pembrolizumab cycles and olaparib during the first three. The pembrolizumab-only arm is closed. Researchers measure PSA response after radiation.
This phase 2 study plans 64 patients. Zin Myint leads at the University of Kentucky, Lexington, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.